Related Experiment Video

Updated: Mar 22, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K

Comment on: Statin use and risk of diabetes mellitus

Mehmet Ali Eren1, Tevfik Sabuncu1, Hüseyin Karaaslan1

  • 1Mehmet Ali Eren, Tevfik Sabuncu, Hüseyin Karaaslan, Department of Endocrinology, Harran University, School of Medicine, 63100 Sanliurfa, Turkey.

World Journal of Diabetes
|April 27, 2016
PubMed

Insights

Pravastatin use, specifically 40 mg/dL, was associated with a 30% reduction in diabetes risk and coronary heart disease risk in the West of Scotland Coronary Prevention study. This finding highlights statins

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Statin therapy is widely prescribed for cardiovascular disease prevention.
  • The potential impact of statins on glucose metabolism and diabetes risk is an area of ongoing research.
  • Understanding drug-specific effects is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate the association between pravastatin use and the risk of developing diabetes mellitus.
  • To assess the effect of pravastatin on coronary heart disease risk within the West of Scotland Coronary Prevention study.

Main Methods:

  • Analysis of data from the West of Scotland Coronary Prevention study.
  • Examination of pravastatin dosage (40 mg/dL) and its correlation with diabetes incidence.
  • Comparison of coronary heart disease risk in patients receiving pravastatin.

Main Results:

  • Pravastatin at a 40 mg/dL dosage demonstrated a 30% reduction in the risk of developing diabetes mellitus.
  • The same dosage of pravastatin was associated with an approximate 30% reduction in coronary heart disease risk.

Conclusions:

  • Pravastatin, at 40 mg/dL, may have a protective effect against both diabetes mellitus and coronary heart disease.
  • These findings contribute to the understanding of statin's role in metabolic and cardiovascular health.

Keywords:
Coronary heart diseaseDiabetes mellitusMyocardial InfarctionPravastatinStatins

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
982
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
909
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
921
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K